OBJECTIVE:To conduct a systematic review with meta-analysis on the clinical safety of finasteride in treatment of benign prostatic hyperplasia ( BPH) , and to compare and analyze the results with related foreign studies . METHODS:Correlative literature with application of single finasteride or finasteride combined with other drugs in treatment of BPH were retrieved .RCT, CCT that related to finasteride were involved .The quality of literature was evaluated , the data were extracted and meta-analysis or qualitative systematic review were conducted .RESULTS:10 RCT/CCT met the inclusion criteria .According to the analysis: finasteride had a curative efficacy with slight adverse reactions .Compared with tamsulosin group , finasteride group had a grater improvement in IPSS score , Qmax and prostate volume , with significant difference ( P 0.05 ) .Compared with finasteride group , finasteride +terazosin group had a greater improvement in prostate volume , IPSS, Ru and Qmax , with significant difference ( P0.05 ) .CONCLUSIONS:Finasteridecan in treatment of BPH can significantly relief the symptoms and reduce the prostate volume with slight adverse reactions .Finasteride combined with tamsulosin or terazosin had a better clinical curative efficacy than the single drug therapy .%目的:对我国非那雄胺治疗(benign prostatic hyperplasia,BPH)的临床安全性进行系统评价和Meta分析,并与国外相关研究进行比较分析.方法:检索关于非那雄胺单药或与其他药品联和应用,治疗良性前列腺增生的文献.纳入与非那雄胺的有关的随机对照试验(randomized controlled trials,RCT)或临床对照试验(clinical controlled trials,CCT).评价纳入文献质量并提取资料,进行Meta分析或作定性系统评价.结果:共纳入10篇RCT/CCT.分析发现:非那雄胺疗效确定,不良反应少.非那雄胺组与坦索罗辛组相比,在国际前列腺症状评分(international prostate symptom score,IPSS)、最大尿流率(maximal urinary flow rate,Qmax)和前列腺体积改善方面差异有统计学意义(P0.05).非那雄胺联合特拉唑嗪与非那雄胺相比,在前列腺体积、IPSS、Ru、Qmax改善方面差异有统计学意义(P0.05).结论:应用非那雄胺治疗BPH,能显著缓解症状,缩小前列腺体积,不良反应少,且非那雄胺与坦索罗辛或特拉唑嗪联合用较单用非那雄胺治疗更为有效.
展开▼
